

ENHANCED LIVER DELIVERY AND SUSTAINED RELEASE OF CURCUMIN WITH DRUG LOADED NANOPARTICLES AFTER INTRAVENOUS ADMINISTRATION IN RATS SURESH KONATHAM¹, BONEPALLY REDDY², JITHAN AUKUNURU^{2, 3*}

For Author affiliations see end of the text
This paper is available online at www.jprhc.in

ABSTRACT:

Liver targeting drug delivery systems can improve the delivery of several drugs useful in the treatment of liver disorders such as cirrhosis and liver cancer. The objective of this study was to prepare the biodegradable nanoparticles containing curcumin, a well-known hepatoprotective agent and further to evaluate the liver targetability and sustained release of curcumin with the developed nanoformulation. Curcumin nanoparticles were prepared by double emulsion (w/o/w) solvent evaporation method using different drug polymer ratios. Poly-ε-caprolactone was used in the preparation. The prepared formulations were evaluated for particles size, surface potential, entrapment efficiency, in vitro release, drug polymer interaction. Four different formulations CNP1, CNP2, CNP3 and CNP4 were prepared. Optimized formulation (CNP3) was evaluated for pharmacokinetics and hepatoprotective activity in CCl₄ induced liver toxicity model after i.v. administration. Optimized formulation was selected based on the size, entrapment efficiency and release characteristics. Curcumin i.v. solution and oral suspension form were used as the reference. Particle size of all formulations was in the range of 300-470 nm and the entrapment efficiencies were in the range of 75-85 %. Drug release from the nanoparticles was sustained both *in vitro* and *in vivo*. Nanoparticle formulation tested *in vivo* demonstrated better pharmacokinetics and pharmacodynamics compared to the reference. Drug levels in the liver were significantly higher with nanoparticulate formulation. Thus, this study successfully prepared a nanoparticulate formulation containing curcumin with polycaprolactone as the polymer. With the developed formulation better liver targetability was achieved.

Key words: cirrhosis, liver targeting, nanoparticles, curcumin, pharmacokinetics, sustained drug release, hepatoprotective activity.

INTRODUCTION

Curcumin (diferuloyl methane; 1, 7-Bis-(4-hydroxy-3-methoxyphenyl)-hepta-1, 6-diene-3, 5-dione) is a major constituent found in the spice turmeric, which is derived from the rhizomes of *Curcuma longa* L. It is commonly used as a dietary spice and colouring agent in cooking and is used as an herb in traditional Indian and Chinese medicine. Curcumin possesses diverse pharmacological effects including anti-inflammatory,

antioxidant, anticancer, antidiabetic, antirheumatic, angiogenic, antifertility, antiviral and anti-infectious activities and wound healing properties.¹ Despite curcumin's multiple medicinal benefits, low oral bioavailability of curcumin continues to be highlighted as a major challenge in developing formulations for clinical efficacy. Lower serum and tissue levels of curcumin are observed irrespective of the route of administration due to extensive intestinal and hepatic metabolism and rapid elimination thus restraining curcumin's bioavailability.²⁻⁴ Curcumin is also found to be photo-sensitive and requires careful handling. In spite of numerous formulations challenges several formulation strategies like nanoparticles, liposomes, complexation with phospholipids and cyclodextrins, solid dispersions are being developed to improve curcumin's bioavailability.⁵⁻⁷ It is also popularly known as a hepatoprotective agent.

Liver is the main site of metabolism for many drugs and xenobiotics. The central role played by liver in the clearance and transformation of chemicals also makes it susceptible to drug induced injury. Liver fibrosis and liver cirrhosis are generally the end result of majority of chronic liver insults. The development of fibrosis, and particularly cirrhosis, are associated with a significant morbidity and mortality. The causes of hepatic fibrosis and cirrhosis are multiple and include congenital metabolic, inflammatory, and toxic liver diseases. In all circumstances, the composition of the hepatic scar is similar.⁸ Many chemicals damage mitochondria, an intracellular organelle that produces energy. Its dysfunction releases excessive amount of oxidants which in turn injures hepatic cells. Activation of some enzymes

in the cytochrome P-450 system such as CYP2E1 also leads to oxidative stress.⁹ This suggests that increase in oxidative stress is the center to the progression of these liver disorders. Further, injury to hepatocyte and bile duct cells lead to accumulation of bile acid inside liver. This promotes further liver damage and enhances inflammation.¹⁰ Non-parenchymal cells such as Kupffer cells, fat storing stellate cells, sinusoidal endothelial cells and leukocytes (i.e., neutrophils and monocytes) have a significant role in the mechanism.¹¹ In all these conditions, curcumin which is both antioxidant as well as antiinflammatory should demonstrate significant benefit in liver toxicity. This was demonstrated by showing the hepatoprotective activity of curcumin. Interestingly, Kupffer cells in the liver are exposed to systemic circulation and are phagocytic in nature.¹² Sinusoidal endothelial cells also exposed to systemic circulation can actively take up particles by endocytosis.¹³ Thus, curcumin can be targeted to liver cells involved in fibrosis and cirrhosis using particulate approach in the way of passive targeting to improve the treatment of these liver disorders. Previous reports clearly indicate that smaller size particles are avidly taken up by liver cells compared to microparticles.¹³ Further, so as to target the liver, the size of the microparticles that can be injected into the systemic circulation is restricted to 6 μm only as the greater size particles are known to reach the lungs and gets lodged in the pulmonary tissues.¹⁴ Also, the amount of the drug released in the cells of interest with nanoparticles after cellular entrapment is far greater than compared to the release from the microparticles after cellular entrapment because of the greater surface area of the nanoparticles.¹⁵ This could result in better pharmacodynamic activity with nanoparticles compared to the microparticles. Thus, the objective of this study was to prepare the biodegradable nanoparticles containing curcumin, a well-known hepatoprotective agent and further to evaluate the liver targetability and sustained release of curcumin with the help of developed nanoformulation.

1. Materials and Methods

1.1. Materials

Curcumin was procured from Yucca Enterprises, Mumbai. Poly- ϵ -caprolactone was procured from Sigma Aldrich, Germany. Poly vinyl alcohol was procured from Qualikems Fine Chemicals Pvt Ltd, New Delhi. Chloroform was procured from Finar chemicals, Ahmedabad, India. HPLC solvents were procured from Merck specialities, Mumbai, India. SGOT and SGPT

kits were purchased from Coral Clinical Systems, Goa, India.

1.2. Methods

1.2.1. Preparation of curcumin nanoparticles

Double emulsion (W/O/W) solvent evaporation method was employed in the preparation of curcumin nanoparticles.¹⁶ Briefly, Curcumin and poly- ϵ -caprolactone previously dissolved in 10 ml of chloroform was emulsified with 5 ml of 3% PVA solution under homogenization for 10min to form a W/O emulsion. This primary emulsion was thereafter poured into the 30 ml of PVA aqueous solution (3 % W/V) and homogenized in a homogenizer (Homogenizer 150 VT, M/S Biologics, Inc –USA) for 15 min to form a W/O/W emulsions.^{17, 18} This multiple emulsion was stirred on a magnetic stirrer till complete evaporation of chloroform. The nanoparticles were obtained by centrifuging the resulted nanoparticulate suspension at 10,000 rpm for 4.5 min. The obtained nanoparticles were washed with phosphate buffer saline (PBS) and dried.

1.2.2. Characterization of the curcumin nanoparticles

Determination of the particle size and the surface potential

The prepared nanoparticles were evaluated for their particle size, polydispersity index(PDI) of size distribution and surface charge potential, by photon correlation spectroscopy (PCS) using Zetasizer 3000 HAS (Malvern Instruments, Malvern, UK). The formulations were diluted 1:1000 with the aqueous phase of the formulation to get a suitable kilo counts per second (kcps). Analysis was performed at 25°C with an angle of detection of 90°. Each sample was measured in triplicate.

Encapsulation efficiency

To determine the encapsulation efficiency, the drug from nanoparticles was extracted with acetonitrile, the obtained solution was evaporated to dryness and reconstituted with 100 μl of mobile phase consisting of acetonitrile/methanol/water/acetic acid (40:23:36:1, v/v/v/v)(water and acetic acid solvents whose pH was adjusted to 2.8 prior to the preparation of mobile phase). The column used was C₁₈ ODS column and the size of silica used in this column was 5 μm and the dimension of the column was 4.6 \times 250mm. The samples were spiked

into HPLC (Cyber Labs, USA) column and analysis was carried out a spectrophotometer at 230 nm.¹⁹

***In vitro* release study**

In vitro release of Curcumin nanoparticles was performed by taking weighed amount of nanoparticles into a dialysis bag (D-70, MWCO 12000-2000, nanoparticles suspended in 1 ml of distilled water), suspended in 50 ml of Phosphate Buffer 7.4 (release medium).²⁰ This entire system was kept at 37°C on magnetic stirrer with 50 rpm. Aliquots were withdrawn at predetermined time intervals and the receptor compartment was replenished with same volume of fresh dialysing medium. The samples were analyzed at 425 nm using UV-Visible spectrophotometer (Elico SL 164 Double beam). The release study was terminated when no more drug is released for more than 48 hours in the release conditions. Data obtained from *in vitro* release studies were fitted to various kinetic equations to find out the mechanism of curcumin release from the nanoparticles.

Drug- polymer interactions

Drug – Polymer interaction was investigated using FTIR. FTIR spectra of drug, polymer, placebo nanoparticles and drug loaded particles were taken using a Thermo Nicolet Nexus 670 Spectrophotometer with KBr pellets.

ANIMAL STUDIES

IN VIVO DRUG RELEASE AND HEPATO PROTECTIVE ACTIVITY OF THE FORMULATION

In Vivo drug release was investigated in male wistar rats. All the animal experiments were conducted according to the rules and guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Chennai, India. The study was approved by Institutional Animal Ethical Committee of Vaagdevi College of Pharmacy, Warangal, registered under CPCSEA, India (Registration No: 1047/ac/07/CPCSEA). The rats were acclimatized with 12 hour dark and 12 hour light cycle at a temperature of 20° C at a humidity of 60% and were fed on standard diet for 10 days prior to the commencement of the experiment. The conditions continued during the next 10 days of experimentation. Rats were divided into three groups,

Research Article

each group containing six rats. Group 1 received 1ml of curcumin solution (15mg/ml DMSO solution) intravenously. Group 2 received 1ml of curcumin nanoparticulate suspension (equivalent to 15mg of curcumin) by intravenous route. Group 3 received 1ml curcumin oral suspension (15mg). After administration of the formulations blood samples were collected at 0.5, 1, 2, 3, 6, 12, 24 hours and 3, 6 and 9 days and plasma was separated. The drug was extracted from the plasma by adding 500 µl of acetonitrile. Curcumin in these samples were estimated using a HPLC (Cyberlab, USA) at 230nm. In case of liver, kidney, colon and brain, the tissue was homogenized and then the drug was extracted with acetonitrile. A HPLC standard curve for the drug in the plasma was generated. The mobile phase consisted of acetonitrile/methanol/water/acetic acid at a ratio of 40:23:36:1, v/v/v/v.

Hepatoprotective activity

Carbon tetrachloride induced liver damage model was used in the evaluation of hepatoprotective activity of the prepared formulations. Male wistar rats (150-180g) were divided into 5 groups containing six rats each. Group 1 received normal saline (1 ml/rat) daily for 9 days. Group 2 received carbon tetrachloride (0.7 ml/kg), administered intraperitoneally on the 3rd, 6th and 9th day consisting of a mixture of CCl₄ and olive oil (25:75). Group 3 received curcumin oral suspension (100 mg/kg) daily for 9 days. Group 4 received curcumin solution (100mg/kg) intravenously, daily for 9 days. Group 5 received curcumin nanoparticulate suspension (equivalent to 100mg/kg of curcumin) intravenously at day one. All groups received CCl₄ at 3rd, 6th and 9th day of the study except normal control. Hepatoprotective activity was quantified by the SGOT (serum glutamate oxaloacetate transaminase), SGPT (serum glutamate pyruvate transaminase) levels and histological studies following a previously published report.²¹

Statistical analysis

Results are expressed as means ± S.E.M. of six rats per treatment group. Data were analyzed using a one-way analysis of variance (ANOVA) followed by Dunnett's test. Differences were considered significant at p≤0.05.

RESULTS

PREPARATION AND CHARACTERIZATION OF CURCUMIN NANOPARTICLES:

Curcumin nanoparticles were successfully prepared by double emulsion solvent evaporation method. Four formulations were prepared by taking different drug to polymer ratios like 1:1, 1:2, 1:3 and 1:4. Compositions of nanoparticles are described in Table 1. The results for particle size, zeta potential and encapsulation efficiency are shown in Table 2. Drug polymer interactions were studied by FTIR; from the spectra we observed that there is no interaction between the drug and polymer. The *in vitro* release studies from curcumin nanoparticles were fitted into various release kinetic models (Table 3). From release profiles (Fig. 1.) it was observed that increase in polymer concentration results in decrease of drug release rate. From all four formulations, the drug release was up to 20% during the first 3 days. The percent cumulative drug release observed was 80%, 86%, 90% and 92% and *in vitro* drug release was sustained up to 6, 7, 9 and 12 days for CNP1, CNP2, CNP3 and CNP4, respectively. Different kinetic release patterns were evaluated. The log percent cumulative drug released was plotted as a function of log time and the slope of the curves was determined as the values of diffusional release exponent (n). The values of diffusional release exponent (n) from the straight lines were noted to be 0.395, 0.410, 0.421 and 0.422 for CNP1, CNP2, CNP3 and CNP4 respectively, which indicated that the release of drug from all formulations followed a Fickian pattern.²²

IN VIVO DRUG RELEASE AND THE HEPATOPROTECTIVE ACTIVITY

Drug levels in the plasma and the tissues were determined using HPLC. The retention time of the drug was 9.6 min. Plasma profile of the drug after nanoparticulate, oral and *i.v.* solution form administration was plotted (Fig. 2.). From the figure it clearly indicates that nanoparticulate formulation sustains the drug release up to 9 days reflecting an increased area under curve. Peak serum concentration of 2.2 μ g/ml was observed within 30 min when curcumin solution was given intravenously. Peak serum concentration of 1.12 μ g/ml was observed within 6 hours when curcumin suspension was given orally. Peak serum concentration of 2.6 μ g/ml was observed within 1 hour when curcumin nanoparticles (CNP3) suspension was given intravenously. Pharmacokinetic parameters were shown in Table 4. Data obtained from hepatoprotective study is shown in Table 5. Nanoparticulate formulation significantly reduces the elevated enzymes levels. From the table it was observed that all formulations were having significant hepatoprotective activity when compared to CCl₄

treated group ($p < 0.05$). Among all the formulations studied, curcumin nanoparticles showed highest hepatoprotective activity (Fig. 3.). The drug levels in various tissues like liver, brain, kidney, and colon were estimated and shown in Table 6. Histopathology of liver is shown in Fig. 4.

DISCUSSIONS

Particle size and entrapment efficiency of the curcumin nanoparticles were increased with increasing the polymer content up to 300 mg. This may be due to high amount of polymer available for coating the drug. Upon increasing the polymer amount, number of layers was increased; this resulted in the increase in particle size and entrapment efficiency. Further increase in the polymer content to 400 mg did not increase the entrapment presumably due to the less availability of the drug to be incorporated. The *in vitro* drug release was fitted into various release models. From the release data we observed that increase in the polymer content delays the drug release due to increased particle size and reduced surface area available for drug release. From all the four formulations studied, formulation CNP3 was selected as optimized formulation because of less PDI, high entrapment efficiency and since the release was prolonged up to 9 days, the study period we selected for determining hepatoprotective activity. From plasma profile it was observed that the drug levels in plasma was lower in case of curcumin when given orally compared to that of curcumin and CNP3 given intravenously. This could be because of lower oral bioavailability of curcumin and significant degradation of free curcumin in the plasma. With the nanoparticulate formulation the drug release was sustained up to 10 days. This could be due to reduction in the elimination and metabolism. From the liver enzyme studies we observed that SGOT and SGPT levels were more in case of CCl₄ treated animals because of tissue damage caused by CCl₄ which releases the enzymes in to the blood stream. A fatty layer was observed in the histopathology of liver. Upon administration of curcumin formulations the enzyme levels was decreased due to the fibrosis caused by the CCl₄ was reversibly cured by the curcumin. The curability of liver toxicity was more for nanoparticles compared to the other formulations because of nanosize particles were instantly taken up by the RES of liver thus the drug was accumulated in the liver and the drug release was more concentrated at the cellular level of liver. This results in the hepatoprotection. After the treatment the fatty layers and number of necrotic cells were reduced due to the hepatoprotective action of curcumin. From tissue

distribution studies it was observed that drug was more concentrated in the liver compared to colon, kidney, and brain. This may be due to nanosize of the particles, which were easily taken up by the RES of liver compared to the other tissues. The drug accumulation order in the different tissues is as follows: liver, colon, kidney and brain. The drug levels in brain were not detected and may due to the presence of blood brain barrier (BBB) which could hinder the transport of curcumin across the barrier. In case of nanoparticles small amount of drug was detected in the brain. This may be due to nanosize of the particles, which are accessible through the BBB.

The results of this study clearly indicate that a nanoparticulate formulation containing curcumin is

better in pharmacokinetic properties and sustained plasma drug levels when compared to higher cumulative doses of curcumin administered via i.v. and oral administrations. The reversal of biochemical end points in a CCl₄ hepatotoxic model is better with nanoparticulate curcumin compared to oral and i.v. curcumin. This suggests that this formulation may be of potential use in the treatment of cirrhosis and fibrosis with curcumin. The results can be extrapolated to other drugs suggesting the significant benefits of nanoparticulate passive targeting of drugs to the liver. Similar formulations could not only be used in fibrosis and cirrhosis but also could be used in the liver cancers and several other liver diseases with additional benefits

Table 1. Compositions of curcumin nanoparticles.

Formulation code	CNP1	CNP2	CNP3	CNP4
Curcumin (mg)	100	100	100	100
Poly-ε-caprolactone (mg)	100	200	300	400

Table 2. The particle size, zeta potential and encapsulation efficiencies of curcumin nanoparticles.

Formulation code	Particle size (mean±SD) nm*	Polydispersity Index (PDI)	Zeta potential (mean±SD)*	% Encapsulation Efficiency (mean±SD)*
CNP1	300 ± 1.63	0.525	2.85±2.33	74.75 ± 3.45
CNP2	20.45 ± 1.63	0.325	2.56±3.54	78.41 ± 2.15
CNP3	364.82 ± 3.25	0.103	2.91±2.83	83.25 ± 1.24
CNP4	464.12± 5.48	0.356	2.81±2.55	85.03 ± 0.75

* n=3

Table 3. The in vitro release studies from curcumin nanoparticles were fitted into various release kinetic models.

Formulation code	Zero order	First order	Higuchi model	Korsmeyer - Peppas model	
	R ²	R ²	R ²	R ²	N
CNP1	0.9271	0.9850	0.9905	0.9910	0.395

CNP2	0.9533	0.9872	0.9947	0.9922	0.410
CNP3	0.9511	0.9909	0.9956	0.9928	0.421
CNP4	0.9223	0.9978	0.9923	0.9918	0.422

Table 4. Pharmacokinetic parameters obtained after administration of curcumin formulations.

Parameter	Curcumin oral suspension (15mg)	Curcumin iv bolus (15 mg)	Curcumin nanoparticles iv
Cmax(µg/ml)	1.12±0.056	2.2±0.024	2.6±0.15
Ke(per hour)	0.106±0.008	0.14±0.004	0.004±0.0008
T _{1/2} (hours)	6.53±0.45	4.69±0.3	165.4134±1.57
Vd(Litres)	8.39±0.95	7.99±0.54	9.23±0.45
Clearance(L/h)	0.8±0.034	1.1798±0.06	0.0386±0.004
AUC _{0-∞} (µg/ml/h)	16.835±2.548	12.713±2.658	387.649±10.54

* Values indicate mean ± standard error mean (S.E.M). n=6

Table 5. Effect of curcumin formulations on enzyme levels in rats with CCl₄ induced hepatotoxicity (Mean ± SEM; n=3)

Groups	SGOT(U/L)	SGPT(U/L)
Normal control(saline)	16.09±1.306	10.73±2.359
CCl ₄ treatment	73.39±2.45 ^b	43.79±3.485 ^b
CCl ₄ + Curcumin oral(100mg/kg)	41.44±3.611 ^a	26.16±2.955 ^a
CCl ₄ + Curcumin i.v (10mg/kg)	33.07±2.571 ^a	20.82±2.767 ^a
CCl ₄ + Curcumin nanoparticles (100mg/kg)	21.02±1.01 ^a	14.81±2.881 ^a



Note: ^a *p* < 0.05 vs CCl₄ treated, ^b *p* < 0.05 vs normal control



Table 6. Curcumin levels in various tissues (µg/mg).

Tissue	Curcumin oral suspension	Curcumin i.v solution	Curcumin nanoparticles
Liver	15.26 ± 0.958	24.78 ± 2.35	56.254 ± 3.54

Colon	8.01 ± 1.2	9.24 ± 1.25	15.614 ± 1.65
Kidney	0.954 ± 0.125	1.256 ± 0.547	2.658 ± 0.954
Brain	Not detectable	Not detectable	0.076 ± 0.015

* All values in $\mu\text{g}/\text{mg}$ of tissue. n=6





CONCLUSION

The nanoparticular formulations of curcumin were successfully prepared using double emulsion (W/O/W) solvent evaporation method. The drug release from the formulations was sustained up to 10 days. The *in vivo* performance of the formulation was better compared to the respective oral and *i.v* formulations. From the distribution studies it was concluded that better liver targeting was achieved by the nanoformulations compared to oral and *i.v*. formulations.

ACKNOWLEDGMENTS

The authors work would like to acknowledge the management of Vaagdevi College of Pharmacy, Warangal, for providing facilities for this work. One of

the Authors, Dr. Aukunuru Jithan would like to acknowledge the Department of Science and Technology (DST), Government of India. This project is partly funded under a SERC-DST Fast Track Proposal for Young Scientists awarded to Dr. Aukunuru Jithan.

Declaration of interest: The authors report no conflicts of interest.

REFERENCES

1. I. Chattopadhyay, K. Biswas, U. Bandyopadhyay, and R.K. Banerjee, Turmeric and curcumin: Biological actions and medicinal applications, *Curr. Sci.* 87, 44(2004).

Research Article

2. P. Anand, A. B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal, Bioavailability of curcumin: problems and promises, *Mol. Phar.* 4, 807(2007).
3. M. H. Pan, T. M. Huang, and Lin JK, Biotransformation of curcumin through reduction and glucuronidation in mice, *Drug Metab. Dispos.* 27, 486 (1999).
4. R. A. Sharma, W. P. Steward, and A. J. Gescher, Pharmacokinetics and pharmacodynamics of curcumin, *Adv. Exp. Med. Biol.* 595, 453 (2007).
5. C. Karikar, A. Maitra, S. Bisht, G. Feldmann, S. Soni, and R. Ravi, Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. *J. Nanobiotechnol.* Available at: <http://www.jnanobiotechnology.com/content/5/1/3>. (2007).
6. K. Maiti, K. Mukherjee, A. Gantait, B. P. Saha, and P. K. Mukherjee, Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats, *Int. J. Pharm.* 330, 155 (2007).
7. W. Tiyaboonchai, W. Tungpradit, and P. Plianbangchang, Formulation and characterization of curcuminoids loaded solid lipid nanoparticles, *Int. J. Pharm.* 337, 299(2007).
8. Manoj Kumar and S. K. Sarin, Is cirrhosis of the liver reversible?, *Indian J. Pediatr.* 74,393 (2007).
9. H. Jaeschke, G. J. Gores, and A. I. Cederbaum, Mechanisms of hepatotoxicity, *Toxicol. Sci.* 65, 166 (2002).
10. T. Patel, L. R. Roberts, B. A. Jones, and G. J. Gores, Dysregulation of apoptosis as a mechanism of liver disease: An overview, *Semin. Liver Dis.* 18, 105 (1998).
11. P. J. De Bleser, T. Niki, V. Rogiers, and A. Geerts, Transforming growth factor-beta gene expression in normal and fibrotic rat liver, *J. Hepatol.* 26, 886 (1997).
12. S. Nagayama, K. Ogawara, Y. Fukuoka, K. Higaki, and T. Kimura, Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics, *Int. J. Phar.* 342, 215(2007).
13. K. Ogawara, M. Yoshida, K. Higaki, T. Kimura, K. Shiraishi, M. Nishikawa, Y. Takakura, and M. Hashida, Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution, *J. Control. Rel.* 59, 15 (1999).
14. P. Chao, M. Deshmukh, H. L. Kutscher, D. Gao, S. S. Rajan, P. Hu, D. L. Laskin, S. Stein, and P. J. Sinko, Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model, *Anticancer Drugs.* 21:65 (2010).
15. J. V. Aukunuru and U. B. Kompella, In vitro delivery of nano- and micro-particles to human retinal pigment epithelial cells (ARPE-19). *Drug Delivery Technology.* Vol. 2 No. 2 March/April 2002, Posted On: 3/28/2008.
16. F. Tewes, E. Munnier, B. Antoon, L.N. Okassa, S. Cohen-Jonathan, H. Marchais, L. Douziech-Eyrolles, M. Soucé, P. Dubois, and I. Chourpa, Comparative study of doxorubicin-loaded poly (lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods, *Eur. J. Pharm. Biopharm.* 66, 488(2007).
17. N. Lamprecht, M. Ubrich, C. M. Hombreiro Perez, M. Lehr, and M. P. Hoffman, Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification, *Int. J. Pharm.* 184, 97(1999).
18. Y. Y. Yang, T. S. Chung, X. L. Bai, and W. K. Chan, Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method, *Chem. Eng. Sci.* 55, 2223 (2000).
19. V. Guduri, J. Aukunuru, and V. M. Reddy, Development of new delivery strategies to increase bioavailability of curcumin, *Int. J. Pharm. Sci. and Nanotech.* 1, 335(2009).
20. C. A. Anuradha and J. Aukunuru, Preparation, characterisation and in vivo evaluation of bis-demethoxy curcumin analogue (BDMCA) nanoparticles, *Trop. J. Pharm. Res.* 9,51 (2010).
21. C. R. Bonepally, J. V. Aukunuru, N. R. Yellu, and M. R. Vanga, Fabrication and investigations on hepatoprotective activity of sustained release biodegradable piperine microspheres, *Int. J. Pharm. Sci. and Nanotech.* 1, 87 (2008).
22. R. S. Langer and A. Peppas, Present and future applications of biomaterials in controlled drug delivery systems, *Biomaterials.* 2, 201(1981).

AUTHORS AFFILIATIONS AND ADDRESS FOR CORRESPONDENCE

¹ Formulation Research and Development, Global Oncology, Dr. Reddys Research Laboratories, Hyderabad, AP, India.

² Vaagdevi College of Pharmacy (Affiliated to Kakatiya University), Ramnagar, Warangal, AP, India, 506001.

³ Mother Teresa College of Pharmacy (Affiliated to Osmania University), NFC Nagar, RR Dist, AP, India-501301

*Corresponding author: Phone: (0091)9849125290, Fax: 0091-870-2455111, email: aukunjv@gmail.com